Formycon AG (LON:0W4N)

London flag London · Delayed Price · Currency is GBP · Price in EUR
29.30
-0.55 (-1.84%)
At close: Jun 27, 2025
-44.30%
Market Cap 423.79M
Revenue (ttm) 57.62M
Net Income (ttm) -103.93M
Shares Out n/a
EPS (ttm) -5.94
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 5,323
Average Volume 6,144
Open 30.05
Previous Close 29.85
Day's Range 28.95 - 30.15
52-Week Range 19.20 - 64.30
Beta 0.58
RSI 56.84
Earnings Date Aug 13, 2025

About Formycon AG

Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides ranibizumab and aflibercept used in the treatment of neovascular age-related macular degeneration, diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranopto, Uptera, and Ravegza brand names, as well as AHZANTIVE, Baiama, and Fovlya brand names. The company’s pipeline includes ustekinumab used in the treatment of Crohn’s disease, ulcerative colitis... [Read more]

Industry Medical - Pharmaceuticals
Sector Healthcare
Founded 1999
Employees 250
Stock Exchange London Stock Exchange
Ticker Symbol 0W4N
Full Company Profile

Financial Performance

Financial numbers in EUR Financial Statements

News

There is no news available yet.